Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A clinician’s handbook for using ctDNA throughout the patient journey
Samantha O. Hasenleithner, Michael R. Speicher
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 80

Showing 26-50 of 80 citing articles:

Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer
Caterina Gianni, Michela Palleschi, Filippo Merloni, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 14197-14197
Open Access | Times Cited: 18
Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis
Aliki Ntzifa, Evi Lianidou
Critical Reviews in Clinical Laboratory Sciences (2023) Vol. 60, Iss. 8, pp. 573-594
Closed Access | Times Cited: 10
Epigenetic modifications of cfDNA in liquid biopsy for the cancer care continuum
Jodie Wong, Rohit Muralidhar, Liang Wang, et al.
Biomedical Journal (2024), pp. 100718-100718
Open Access | Times Cited: 3
Very Small Embryonic-Like Stem Cells Transform Into Cancer Stem Cells and Are Novel Candidates for Detecting/Monitoring Cancer by a Simple Blood Test
Deepa Bhartiya, Nripen Sharma, Shruti Dutta, et al.
Stem Cells (2023) Vol. 41, Iss. 4, pp. 310-318
Closed Access | Times Cited: 9
ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach
Lærke Rosenlund Nielsen, Simone Stensgaard, Peter Meldgaard, et al.
Cancer Treatment and Research Communications (2024) Vol. 39, pp. 100802-100802
Open Access | Times Cited: 2
Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression
Eva Valentina Klocker, Samantha O. Hasenleithner, Rupert Bartsch, et al.
Molecular Oncology (2024)
Open Access | Times Cited: 2
Prenatal cell-free DNA testing of women with pregnancy-associated cancer: a retrospective cross-sectional study
Catharina J. Heesterbeek, Vivianne C. G. Tjan‐Heijnen, Joosje H. Heimovaara, et al.
The Lancet Regional Health - Europe (2024) Vol. 45, pp. 101024-101024
Open Access | Times Cited: 2
Lower Circulating Cell-Free Mitochondrial DNA Is Associated with Heart Failure in Type 2 Diabetes Mellitus Patients
Tatyana A. Berezina, M. P. Kopytsya, O. V. Petyunina, et al.
Cardiogenetics (2023) Vol. 13, Iss. 1, pp. 15-30
Open Access | Times Cited: 7
The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization
Abel J. Bronkhorst, Stefan Holdenrieder
Medizinische Genetik (2023) Vol. 35, Iss. 4, pp. 201-235
Open Access | Times Cited: 6
Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian Cancer
Ricardo Roque, Ilda Patrícia Ribeiro, Margarida Figueiredo-Dias, et al.
Biology (2024) Vol. 13, Iss. 2, pp. 88-88
Open Access | Times Cited: 1
Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
Lovisa Falkman, Anders Sundin, Britt Skogseid, et al.
Upsala Journal of Medical Sciences (2024) Vol. 129, pp. e10660-e10660
Open Access | Times Cited: 1
Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer
Yael Bar, Jennifer C. Keenan, Andrzej Niemierko, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Liquid profiling for patients with advanced cancer is ready for clinical integration
Samantha O. Hasenleithner, Ellen Heitzer
memo - Magazine of European Medical Oncology (2024) Vol. 17, Iss. 3, pp. 182-189
Open Access | Times Cited: 1
Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer
Rongqi Jiang, Cheng Xu, Ping Li, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Circulating Cell-Free Nuclear DNAs Predicted an Improvement of Systolic Left Ventricular Function in Individuals with Chronic Heart Failure with Reduced Ejection Fraction
Tatyana A. Berezina, Oleksandr O. Berezin, Michael Lichtenauer, et al.
(2024)
Open Access | Times Cited: 1
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab
Yehia I. Mohamed, Sunyoung S. Lee, Tarık Demir, et al.
Cancer Biomarkers (2024) Vol. 41, Iss. 1, pp. 83-91
Closed Access | Times Cited: 1
Advancements in pathology: Digital transformation, precision medicine, and beyond
S. Ahuja, Sufian Zaheer
Journal of Pathology Informatics (2024), pp. 100408-100408
Open Access | Times Cited: 1
Circulating tumour DNA in colorectal cancer management
Ryan Cohen, Cameron Platell, Melanie J. McCoy, et al.
British journal of surgery (2023) Vol. 110, Iss. 7, pp. 773-783
Open Access | Times Cited: 4
Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications
Claudia Parisi, Marco Tagliamento, Laïla Belcaid, et al.
The Journal of Liquid Biopsy (2023) Vol. 1, pp. 100007-100007
Open Access | Times Cited: 4
NGS method for parallel processing of high quality, damaged or fragmented input material using target enrichment
Anna Lyander, Anna Gellerbring, Moa Hägglund, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Tracking tumor evolution during the first-line treatment in brain glioma via serial profiling of cell-free tumor DNA from tumor in situ fluid
Zhiyuan Sheng, Chaojie Bu, Jie Mei, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
GCparagon: evaluating and correcting GC biases in cell-free DNA at the fragment level
Benjamin Spiegl, Faruk Kapidzic, Sebastian Röner, et al.
NAR Genomics and Bioinformatics (2023) Vol. 5, Iss. 4
Open Access | Times Cited: 3
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring?
Mara Serena Serafini, Elisabetta Molteni, Eleonora Nicolò, et al.
The Journal of Liquid Biopsy (2023) Vol. 3, pp. 100132-100132
Open Access | Times Cited: 3
Circulating tumor DNA: current implementation issues and future challenges for clinical utility
Qilin Hu, Lüjun Chen, Kerui Li, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2023) Vol. 62, Iss. 11, pp. 2094-2110
Closed Access | Times Cited: 3
How to detect cancer early using cell-free DNA
Samantha O. Hasenleithner, Michael R. Speicher
Cancer Cell (2022) Vol. 40, Iss. 12, pp. 1464-1466
Open Access | Times Cited: 6

Scroll to top